Search Result
Results for "
bone mineralization
" in MedChemExpress (MCE) Product Catalog:
4
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-D0886
-
|
|
Phosphatase
Endogenous Metabolite
ERK
|
Metabolic Disease
Cancer
|
|
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .
|
-
-
- HY-P0059
-
Teriparatide
Maximum Cited Publications
11 Publications Verification
Human parathyroid hormone-(1-34); hPTH (1-34)
|
PTHR
Thyroid Hormone Receptor
|
Others
Cancer
|
|
Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research .
|
-
-
- HY-126304
-
|
|
Phosphatase
Endogenous Metabolite
ERK
|
Metabolic Disease
|
|
β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .
|
-
-
- HY-N1499
-
-
-
- HY-108786
-
|
ENB-0040
|
Phosphatase
|
Metabolic Disease
|
|
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
|
-
-
- HY-B0657A
-
|
Clodronate disodium salt
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis .
|
-
-
- HY-D0835A
-
|
Hydroxyapatite (<50 nm)
|
Biochemical Assay Reagents
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Hydroxylapatite (Hydroxyapatite) (<50 nm) is a natural form of calcium phosphate and is the main mineral component of bones and teeth. Hydroxylapatite (<50 nm) can stimulate the expression and secretion of collagen in primary human dermal fibroblasts. Hydroxylapatite (<50 nm) has good biocompatibility, bioactivity, and bone conductivity, making it suitable for targeted drug or nucleic acid delivery. Hydroxylapatite (<50 nm) can be used in research on osteoarthritis, gout, and atherosclerosis .
|
-
-
- HY-Y1353
-
|
|
Biochemical Assay Reagents
|
Others
Metabolic Disease
|
|
Di-tert-butyl dicarbonate (tBOC) is a covalent modification agent for hydroxyl groups (-OH) on the chitosan molecular chain. Di-tert-butyl dicarbonate selectively modifies chitosan and stabilizes the material structure through hydrophobic encapsulation. Di-tert-butyl dicarbonate reacts with the -OH groups of chitosan to form a hydrophobic layer, and in conjunction with triethylamine (TEA), removes trifluoroacetic acid (TFA) salts produced during the electrospinning process, preserving the nanofiber structure and high porosity of the membrane, and improving the material's cytocompatibility and mineralization-promoting ability. Di-tert-butyl dicarbonate can be used in research in the field of guided bone regeneration (GBR) .
|
-
-
- HY-A0020
-
|
ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
|
VD/VDR
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
|
-
-
- HY-D0835
-
|
Hydroxyapatite (25-45 μm)
|
Others
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Hydroxylapatite (Hydroxyapatite) (25-45 μm) is a natural form of calcium phosphate and is the main mineral component of bones and teeth. Hydroxylapatite (25-45 μm) can stimulate the expression and secretion of collagen in primary human dermal fibroblasts. Hydroxylapatite (25-45 μm) has good biocompatibility, bioactivity, and bone conductivity, making it suitable for targeted drug or nucleic acid delivery. Hydroxylapatite (25-45 μm) can be used in research on osteoarthritis, gout, and atherosclerosis .
|
-
-
- HY-W110927
-
|
|
Biochemical Assay Reagents
Fluorescent Dye
|
Others
|
|
Alizarin red S indicator (C.I. 58005) is a reductively active (quinone-based) anthraquinone dye that forms complexes with metal ions (such as zirconium, calcium) or boric acid to label calcium deposition and perform electrochemical sensing functions. Alizarin Red S undergoes reversible redox reactions (for electrochemical detection) and irreversible chelation (for bone staining). Alizarin Red S is mainly used in bone metabolism research (labeling mineralized tissue), sugar detection (boric acid-sugar competition system) and metal ion sensing (such as zirconium ion detection), and can be used in osteoporosis and metabolic disease research .
|
-
-
- HY-10199A
-
|
MK-677 free base; MK-0677 free base
|
GHSR
Insulin Receptor
|
Neurological Disease
Metabolic Disease
|
|
Ibutamoren (MK-677 free base; MK-0677 free base) is an orally active non-peptide growth hormone secretagogue receptor agonist. Ibutamoren activates signal cascades by mimicking endogenous ligands, triggers pulsatile release of growth hormone from the pituitary gland, and increases serum levels of IGF-1 and insulin-like growth factor-binding protein 3. Ibutamoren not only increases the frequency of growth hormone pulses in male individuals, but also promotes elevated bone formation markers in female individuals with postmenopausal osteoporosis. The combination of Ibutamoren with Alendronate sodium hydrate (HY-11101) significantly increases bone mineral density at the femoral neck. However, Ibutamoren may cause mild, reversible adverse reactions such as increased appetite, fluid retention, and elevated fasting blood glucose. Ibutamoren has been widely used in studies related to idiopathic growth hormone deficiency, sarcopenia, Alzheimer's disease, and osteoporosis .
|
-
-
- HY-119443
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Neridronate is an aminobisphosphonate. Neridronate induces osteoblast differentiation, enhances alkaline phosphatase activity and mineralized nodule formation. Neridronate inhibits endothelial cell proliferation, fibroblast growth factor-2-induced capillary-like tube formation, and angiogenesis. Neridronate can be used for osteogenesis imperfecta and Paget’s disease of bone .
|
-
-
- HY-121075
-
|
|
Fluorescent Dye
Reverse Transcriptase
HIV
RSV
|
Infection
Endocrinology
Cancer
|
|
Alizarin complexone is a calcium-binding fluorescent dye. Alizarin complexone stains mineralized areas of bone by binding to calcium crystals. Alizarin complexone inhibits the reverse transcriptase activity of RAV-2, HIV-1, and RSV with IC50 values of 3.8 μg/mL, 45 μg/mL, and 100 μg/mL, respectively. Alizarin complexone exhibits antiviral activity against HIV-1 and RSV. Alizarin complexone delays RSV-induced tumor induction in chickens .
|
-
-
- HY-103322
-
|
|
PKA
Potassium Channel
|
Metabolic Disease
Cancer
|
|
6-Bnz-cAMP sodium, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP sodium does not activate the Epac signaling pathway. It inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP sodium activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. It can be used in studies related to bone tissue repair and regeneration .
|
-
-
- HY-W145486
-
|
|
Environmental Pollutants
Biochemical Assay Reagents
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Calcium gluconate is an orally effective calcium salt supplement . Calcium gluconate reduces elevated serum potassium, decreased serum calcium, and postoperative myalgia associated with succinylcholine administration. Calcium gluconate restores calcium homeostasis, skeletal integrity, bone mineralization and bone density, and maintains levels of parathyroid hormone, bone resorption markers and osteoclasts. Calcium gluconate reverses LPS (HY-D1056)-induced ERK phosphorylation, inflammatory cytokine release and acute lung injury, alleviates airway inflammatory damage and suppresses immune responses. Calcium gluconate can be used in research related to postoperative myalgia, osteoporosis/osteomalacia and acute lung injury .
|
-
-
- HY-B0657
-
|
Clodronate
|
Apoptosis
|
Metabolic Disease
Cancer
|
|
Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis .
|
-
-
- HY-A0020S
-
|
|
VD/VDR
|
Metabolic Disease
|
|
Eldecalcitol-d6 is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.
|
-
-
- HY-P4823
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .
|
-
-
- HY-107245
-
|
|
Estrogen Receptor/ERR
Sirtuin
RUNX
|
Metabolic Disease
|
|
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
|
-
-
- HY-P5832
-
|
|
TGF-beta/Smad
RUNX
|
Metabolic Disease
|
|
BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research .
|
-
-
- HY-W423191
-
|
4-O-α-D-Glucopyranosyl-D-gluconic acid
|
Nuclear Factor of activated T Cells (NFAT)
Bacterial
|
Infection
Metabolic Disease
|
|
Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H2O2)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation .
|
-
-
- HY-170788
-
|
|
Phosphodiesterase (PDE)
|
Metabolic Disease
|
|
PDE7A-IN-1 is an orally active and selective PDE7A inhibitor with an IC50 of 0.0037 μM against PDE7A. PDE7A-IN-1 shows excellent isozyme selectivity over PDE7B. PDE7A-IN-1 elevates intracellular cAMP levels, suppresses ECR5 enhancer activity and reduces sclerostin expression. PDE7A-IN-1 significantly increases bone mineral density in rats. PDE7A-IN-1 can be used for the study of osteoporosis .
|
-
-
- HY-B2203
-
|
|
Phosphatase
|
Metabolic Disease
|
|
Monocalcium glycerophosphate is an inhibitor of intestinal alkaline phosphatase F3, and it has anti-cavity properties. Monocalcium glycerophosphate is a source of calcium and phosphorus in total parenteral nutrition solutions, helps prevent the mineralization and development of bones from intravenous nutrition, and maintains the integrity of the intestinal epithelium .
|
-
-
- HY-108044
-
|
|
Cathepsin
SARS-CoV
|
Metabolic Disease
|
|
ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .
|
-
-
- HY-P5522A
-
|
L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride
|
NOD-like Receptor (NLR)
NF-κB
MAP3K
MEK
ERK
p38 MAPK
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
TriDAP dihydrochloride (L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP dihydrochloride enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP dihydrochloride downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP dihydrochloride decreases IκBα levels and increases p65 levels. TriDAP dihydrochloride induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP dihydrochloride increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP dihydrochloride can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection .
|
-
-
- HY-15830
-
|
25,26-Dihydroxycholecalciferol
|
VD/VDR
Drug Metabolite
Drug Derivative
Calcium Channel
|
Metabolic Disease
|
|
25,26-Dihydroxyvitamin D3 (25,26-Dihydroxycholecalciferol) is a dihydroxylated derivative and metabolite of Vitamin D3 (HY-15398). 25,26-Dihydroxyvitamin D3 moderately increases serum calcium levels when the initial serum calcium level is low. 25,26-Dihydroxyvitamin D3 promotes intestinal calcium absorption in vitamin D-deficient rats fed a low-calcium diet. 25,26-Dihydroxyvitamin D3 is applicable to research related to osteomalacia .
|
-
-
- HY-P0284
-
|
|
MMP
|
Inflammation/Immunology
|
|
C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).
|
-
-
- HY-P0284A
-
|
|
MMP
|
Inflammation/Immunology
|
|
C-telopeptide TFA, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD) .
|
-
-
- HY-135702
-
|
|
NF-κB
|
Others
|
|
UBS109, as a curcumin analogue, can promote the differentiation and mineralization of osteoblasts. UBS109 shows to regulate bone cell function by activating Smad and inhibiting NF-kB. UBS109 can be used in bone tissue engineering and osteoporosis research .
|
-
-
- HY-N8837
-
|
|
MMP
|
Metabolic Disease
|
|
Trifloroside is a secoiridoid glycoside with antioxidant effects. Trifloroside induces osteogenic effects through osteoblast differentiation, adhesion, migration, and mineral apposition. Trifloroside has the potential for osteoblast-mediated bone diseases research .
|
-
-
- HY-P0059A
-
|
Human parathyroid hormone-(1-34) acetate hydrate; hPTH (1-34) acetate hydrate
|
PTHR
Thyroid Hormone Receptor
|
Others
Cancer
|
|
Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) is a PTH1 receptor agonist. Teriparatide acetate hydrate (Human parathyroid hormone-(1-34) acetate hydrate) can be used for osteoporosis research .
|
-
-
- HY-P5522
-
|
L-Ala-γ-D-Glu-meso-diaminopimelic acid
|
NOD-like Receptor (NLR)
NF-κB
MAP3K
MEK
ERK
p38 MAPK
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection .
|
-
-
- HY-159595
-
|
|
LDLR
PCSK9
|
Metabolic Disease
Inflammation/Immunology
|
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
|
-
-
- HY-P0007
-
|
Carbocalcitonin
|
Drug Intermediate
|
Metabolic Disease
|
|
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .
|
-
-
- HY-A0020R
-
|
ED-71 (Standard); 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3 (Standard)
|
Reference Standards
VD/VDR
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Eldecalcitol (Standard) is the analytical standard of Eldecalcitol. This product is intended for research and analytical applications. Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
|
-
-
- HY-103578
-
|
|
Androgen Receptor
|
Cancer
|
|
S-40503 is an orally active and selective androgen receptor modulator. S-40503 significantly increases the bone mineral density (BMD) and biomechanical strength of femoral cortical bone .
|
-
-
- HY-D2132
-
|
|
Fluorescent Dye
|
Cancer
|
|
Sulfo-Cy5.5-ALN is a fluorescent labeled alendronate, which targets bone. Sulfo-Cy5.5-ALN binds to hydroxyapatite and differentiated osteoblasts in vitro. Sulfo-Cy5.5-ALN selectively binds to the mineralized areas of the tumor. Sulfo-Cy5.5-ALN can be used to detect bone overgrowth in prostate bone metastasis .
|
-
-
- HY-N1499R
-
|
|
Reference Standards
Wnt
β-catenin
TGF-beta/Smad
Bacterial
|
Infection
Metabolic Disease
Inflammation/Immunology
|
|
Nystose (Standard) is the analytical standard of Nystose. This product is intended for research and analytical applications. Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose. Nystose exhibits prebiotic, immunomodulatory, and metabolism regulating activities. Nystose promotes the bone mineralization by activating the Wnt/β-catenin signaling pathway .
|
-
-
- HY-169703
-
SPA0355
1 Publications Verification
|
RANKL/RANK
p38 MAPK
Akt
NF-κB
|
Inflammation/Immunology
|
|
SPA0355 is a thiourea derivative that has antioxidant and anti-inflammatory properties. SPA0355 inhibits the RANKL (receptor activator of nuclear factor κB ligand) induced osteoclast formation in primary bone marrow-derived macrophages. SPA0355 also suppresses the activation of the MAPKs, Akt, and NF-κB pathways. Additionally, SPA0355 promotes osteoblast differentiation, increases alkaline phosphatase activity, and enhances mineral nodule formation. SPA0355 can protect ovariectomized mice from bone loss by stimulating osteoblast differentiation and inhibiting osteoclast resorption, making it useful for studying postmenopausal osteoporosis .
|
-
-
- HY-P991365
-
|
|
Transmembrane Glycoprotein
|
Endocrinology
|
|
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-117182
-
|
|
Apoptosis
VD/VDR
RAR/RXR
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .
|
-
-
- HY-117817
-
|
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Ranelic acid is an organic acid with metal cation chelating activity. Ranelic acid can be used to inhibit osteoporosis and increase bone mineral density. Ranelic acid derivatives exhibit highly substituted thiophene ring structures .
|
-
-
- HY-153258
-
|
|
CaSR
|
Metabolic Disease
|
|
CaSR
antagonist-1 is a calcium sensing receptor (CaSR) antagonist
with an IC50 value of 50 nM. CaSR
antagonist-1 can be used for the research of disorders associated with abnormal
bone or mineral homeostasis such as osteoporosis .
|
-
-
- HY-15099
-
|
VEL 0230
|
Cathepsin
|
Inflammation/Immunology
|
|
NC 2300 (VEL-0230)is a selective and orally active cysteine cathepsin inhibitor with the IC50 values of 284, 34.5, and 186 nM for cathepsin B, K, and S, respectively.NC 2300 can be used for study of diseases involving bone mineral disorders .
|
-
-
- HY-150186
-
|
|
RXFP Receptor
|
Metabolic Disease
|
|
RXFP2 agonist 2 is a selective, orally active and allosteric RXFP2 agonist with an EC50 value of 0.38 μM. RXFP2 agonist 2 induces osteoblast mineralization. RXFP2 agonist 2 increases bone formation in female mice. RXFP2 agonist 2 has the potential for the research of osteoporosis .
|
-
-
- HY-119443R
-
|
|
Reference Standards
Phosphatase
|
Metabolic Disease
Inflammation/Immunology
|
|
Neridronate (Standard) is the analytical standard of Neridronate (HY-119443). This product is intended for research and analytical applications. Neridronate is an aminobisphosphonate. Neridronate induces osteoblast differentiation, enhances alkaline phosphatase activity and mineralized nodule formation. Neridronate inhibits endothelial cell proliferation, fibroblast growth factor-2-induced capillary-like tube formation, and angiogenesis. Neridronate can be used for osteogenesis imperfecta and Paget’s disease of bone .
|
-
-
- HY-W320523
-
|
|
Fluorescent Dye
Reverse Transcriptase
HIV
RSV
|
Infection
Metabolic Disease
Cancer
|
|
ALizarin complexone dihydrate is the dehydrate of Alizarin complexone (HY-121075). Alizarin complexone is a calcium-binding fluorescent dye. Alizarin complexone stains mineralized areas of bone by binding to calcium crystals. Alizarin complexone inhibits the reverse transcriptase activity of RAV-2, HIV-1, and RSV with IC50 values of 3.8 μg/mL, 45 μg/mL, and 100 μg/mL, respectively. Alizarin complexone exhibits antiviral activity against HIV-1 and RSV. Alizarin complexone delays RSV-induced tumor induction in chickens .
|
-
-
- HY-121075R
-
|
|
Reference Standards
Reverse Transcriptase
Fluorescent Dye
HIV
RSV
|
Infection
Endocrinology
Cancer
|
|
Alizarin complexone (Standard) is the analytical standard of Alizarin complexone (HY-121075). This product is intended for research and analytical applications. Alizarin complexone is a calcium-binding fluorescent dye. Alizarin complexone stains mineralized areas of bone by binding to calcium crystals. Alizarin complexone inhibits the reverse transcriptase activity of RAV-2, HIV-1, and RSV with IC50 values of 3.8 μg/mL, 45 μg/mL, and 100 μg/mL, respectively. Alizarin complexone exhibits antiviral activity against HIV-1 and RSV. Alizarin complexone delays RSV-induced tumor induction in chickens .
|
-
-
- HY-137381
-
|
N6-Benzoyl-cAMP
|
PKA
Potassium Channel
|
Metabolic Disease
|
|
6-Bnz-cAMP, a derivative of cyclic adenosine monophosphate (cAMP), is a selective PKA activator with inhibitory activity against the bTREK-1 K + channel. 6-Bnz-cAMP does not activate the Epac signaling pathway. 6-Bnz-cAMP inhibits the bTREK-1 K + channel via a voltage-independent, ATP-dependent mechanism that is independent of the PKA/Epac/calmodulin kinase/MAP kinase pathway. 6-Bnz-cAMP activates CREB phosphorylation to regulate osteoblast-specific gene expression, induces osteoblast differentiation, promotes extracellular matrix mineralization, supports osteoblast proliferation, and shows no cytotoxicity toward osteoblasts. 6-Bnz-cAMP can be used in studies related to bone tissue repair and regeneration .
|
-
- HY-138089
-
|
|
Androgen Receptor
Estrogen Receptor/ERR
LDLR
|
Metabolic Disease
Cancer
|
|
17β-Hydroxy exemestane (17-H-EXE) is the primary active metabolite of Exemestane (HY-13632). 17β-Hydroxy exemestane is an aromatase inhibitor (IC50 = 69 nM) and an androgen receptor (AR) agonist (IC50 = 39.6 nM) that is selective for AR over estrogen receptor α (ERα; IC50 = 21.2 μM). 17β-Hydroxy exemestane stimulates growth of AR- and ERα-positive MCF-7 (EC50= 2.7 μM) and T47D breast cancer cells (EC50s = 0.43 and 1500 nM for AR- and ER-mediated growth, respectively) and inhibits proliferation of testosterone-treated aromatase-overexpressing MCF-7 cells. 17β-Hydroxy exemestane inhibits increases in serum cholesterol and LDL levels and prevents decreases in bone mineral density in the lumbar vertebrae and femur, as well as femoral bending strength and compressive strength of the fifth lumbar vertebrae in ovariectomized rats .
|
-
- HY-159701A
-
|
|
Drug Intermediate
|
Others
|
|
DBCO-PEG2000-alendronic acid sodium is a PEG linker conjugated with alendronic acid (HY-B0631) and DBCO groups. Alendronic acid possesses bone-targeting properties, enabling strong chelation with calcium ions in bone and hydroxyapatite, and exhibits high specific adsorption on mineralized tissues such as bones and teeth. This compound can be applied to construct bone-targeted drug delivery systems and bone tissue imaging probes.
|
-
- HY-N19066
-
|
|
Others
|
Metabolic Disease
|
|
Cissus quadrangularis extract contains a variety of bioactive compounds, such as flavonoids, phenolic acids, carotenoids, triterpenoids, vitamins, 3-ketosteroids, minerals, and sterols. Cissus quadrangularis extract can promote fracture healing, reduce bone loss, and increase bone density.
|
-
- HY-122075
-
|
|
Others
|
Metabolic Disease
|
|
FR 78844 is a potent and orally active bone resorption inhibitor. FR 78844 has the potential for the research of diabetes associated osteopenia .
|
-
- HY-108044R
-
|
|
Reference Standards
Cathepsin
SARS-CoV
|
Metabolic Disease
|
|
ONO-5334 (Standard) is the analytical standard of ONO-5334 (HY-108044). This product is intended for research and analytical applications. ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with Ki values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC50 value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease .
|
-
- HY-181887
-
|
|
Keap1-Nrf2
NF-κB
p38 MAPK
|
Metabolic Disease
|
|
Nrf2 activator-23 is an orally active Keap1 binder and Nrf2 activator, with KD values of 28.68 nM and 54.55 nM for Keap1 and its Kelch domain, respectively. Nrf2 activator-23 disrupts the Keap1-Nrf2 interaction, reduces ubiquitination and degradation of Nrf2, and activates the Nrf2 signaling pathway. Nrf2 activator-23 inhibits RANKL-induced osteoclast formation, bone resorptive activity, ROS production, and activation of the MAPK and NF-κB signaling pathways, while downregulating the expression of osteoclast-specific genes and proteins. Nrf2 activator-23 attenuates bone loss and reduces osteoclast formation in vivo without affecting osteoblast differentiation and mineralization. Nrf2 activator-23 can be used for the research of osteoporosis .
|
-
- HY-159978
-
|
|
Sodium Phosphate Cotransporter
|
Metabolic Disease
Inflammation/Immunology
|
|
EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) .
|
-
-
-
HY-L131
-
|
|
886 compounds
|
|
Ossification is a tightly regulated process, performed by specialized cells called osteoblasts. Dysregulation of this process may cause inadequate or excessive mineralization of bones or ectopic calcification, all of which have grave consequences for human health.
Osteoblasts play important roles in the process of osteogenesis and prevention of osteonecrosis. Osteoblast formation and bone formation are regulated by hormones, growth factors, cytokines, etc.
MCE offers a unique collection of 886 bone formation compounds with identified and potential inducing osteogenesis activity. MCE bone formation compound library is a useful tool for the study of bone disease drugs and pharmacology.
|
| Cat. No. |
Product Name |
Type |
-
- HY-D2132
-
|
|
Fluorescent Dye
|
|
Sulfo-Cy5.5-ALN is a fluorescent labeled alendronate, which targets bone. Sulfo-Cy5.5-ALN binds to hydroxyapatite and differentiated osteoblasts in vitro. Sulfo-Cy5.5-ALN selectively binds to the mineralized areas of the tumor. Sulfo-Cy5.5-ALN can be used to detect bone overgrowth in prostate bone metastasis .
|
| Cat. No. |
Product Name |
Type |
-
- HY-W110927
-
|
|
Biochemical Assay Reagents
|
|
Alizarin red S indicator (C.I. 58005) is a reductively active (quinone-based) anthraquinone dye that forms complexes with metal ions (such as zirconium, calcium) or boric acid to label calcium deposition and perform electrochemical sensing functions. Alizarin Red S undergoes reversible redox reactions (for electrochemical detection) and irreversible chelation (for bone staining). Alizarin Red S is mainly used in bone metabolism research (labeling mineralized tissue), sugar detection (boric acid-sugar competition system) and metal ion sensing (such as zirconium ion detection), and can be used in osteoporosis and metabolic disease research .
|
-
- HY-W145486
-
|
|
Biochemical Assay Reagents
|
|
Calcium gluconate is an orally effective calcium salt supplement . Calcium gluconate reduces elevated serum potassium, decreased serum calcium, and postoperative myalgia associated with succinylcholine administration. Calcium gluconate restores calcium homeostasis, skeletal integrity, bone mineralization and bone density, and maintains levels of parathyroid hormone, bone resorption markers and osteoclasts. Calcium gluconate reverses LPS (HY-D1056)-induced ERK phosphorylation, inflammatory cytokine release and acute lung injury, alleviates airway inflammatory damage and suppresses immune responses. Calcium gluconate can be used in research related to postoperative myalgia, osteoporosis/osteomalacia and acute lung injury .
|
-
- HY-W423191
-
|
4-O-α-D-Glucopyranosyl-D-gluconic acid
|
Biochemical Assay Reagents
|
|
Maltobionic acid (4-O-α-D-Glucopyranosyl-D-gluconic acid) is an orally active oligosaccharide and iron chelator with antibacterial activity. Maltobionic acid inhibits the expression of NFATc1, suppresses osteoclast differentiation, inhibits bone resorption, and increases serum calcitonin levels. Maltobionic acid protects mammalian cells from hydrogen peroxide (H2O2)-induced oxidative damage; resists fermentation by the gut microbiota; and exhibits anti-digestive and anti-fermentative properties. Maltobionic acid can be used in research related to osteoporosis, bacterial infections, and constipation .
|
-
- HY-W320523
-
|
|
Biochemical Assay Reagents
|
|
ALizarin complexone dihydrate is the dehydrate of Alizarin complexone (HY-121075). Alizarin complexone is a calcium-binding fluorescent dye. Alizarin complexone stains mineralized areas of bone by binding to calcium crystals. Alizarin complexone inhibits the reverse transcriptase activity of RAV-2, HIV-1, and RSV with IC50 values of 3.8 μg/mL, 45 μg/mL, and 100 μg/mL, respectively. Alizarin complexone exhibits antiviral activity against HIV-1 and RSV. Alizarin complexone delays RSV-induced tumor induction in chickens .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0059
-
Teriparatide
Maximum Cited Publications
11 Publications Verification
Human parathyroid hormone-(1-34); hPTH (1-34)
|
PTHR
Thyroid Hormone Receptor
|
Others
Cancer
|
|
Teriparatide (Human parathyroid hormone-(1-34)) is a PTH1 receptor agonist. Teriparatide (Human parathyroid hormone-(1-34)) can be used for osteoporosis research .
|
-
- HY-P5284
-
|
|
Peptides
|
Others
|
|
RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization) .
|
-
- HY-P4823
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
pTH (1-37) (human) is a fragment of parathyroid hormone (PTH). pTH (1-37) (human) induces the cAMP formation and increases alkaline phosphatase activity. pTH (1-37) (human) increases growth, bone calcium content, and bone mineral density (BMD) in uremic animals. pTH (1-37) (human) has the potential for the research of osteoporosis .
|
-
- HY-107245
-
|
|
Estrogen Receptor/ERR
Sirtuin
RUNX
|
Metabolic Disease
|
|
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
|
-
- HY-P5832
-
|
|
TGF-beta/Smad
RUNX
|
Metabolic Disease
|
|
BMP2-derived peptide is an osteogenic inducer and BMP receptor ligand. BMP2-derived peptide binds to BMP receptors on the cell surface to form a complex, activates the downstream Smad signaling pathway, and regulates the expression of osteogenic transcription factors. BMP2-derived peptide effectively promotes the adhesion, proliferation, osteogenic differentiation and mineralization of bone marrow mesenchymal stem cells, significantly up-regulates the mRNA levels of OCN, Runx2 and type I collagen, and increases alkaline phosphatase activity and calcium deposition. BMP2-derived peptide induces osteoblast differentiation and ectopic bone regeneration, and improves cranial bone defect repair. Meanwhile, BMP2-derived peptide enhances the cytocompatibility of mesoporous silica nanoparticles, synergistically increases osteogenic activity with Dexamethasone (HY-14648), serving as an important tool for bone defect repair research .
|
-
- HY-P5522A
-
|
L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride
|
NOD-like Receptor (NLR)
NF-κB
MAP3K
MEK
ERK
p38 MAPK
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
TriDAP dihydrochloride (L-Ala-γ-D-Glu-meso-diaminopimelic acid dihydrochloride) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP dihydrochloride enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP dihydrochloride downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP dihydrochloride decreases IκBα levels and increases p65 levels. TriDAP dihydrochloride induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP dihydrochloride increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP dihydrochloride can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection .
|
-
- HY-P3637
-
|
|
Peptides
|
Inflammation/Immunology
|
|
AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG promotes bone-ossification. AVSEHQLLHDKGKSIQDLRRRFFLHHLI-{Aib}-EIHTAYRFGG can be used in the research of diseases or disorders related to osteogenic defects or bone mineral density (BMD) decreasing, such as osteoporosis .
|
-
- HY-P0284
-
|
|
MMP
|
Inflammation/Immunology
|
|
C-telopeptide, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD).
|
-
- HY-P0284A
-
|
|
MMP
|
Inflammation/Immunology
|
|
C-telopeptide TFA, a cross-linked peptide of type I collagen, is released during bone resorption and has been correlated with bone mineral density (BMD) .
|
-
- HY-P5522
-
|
L-Ala-γ-D-Glu-meso-diaminopimelic acid
|
NOD-like Receptor (NLR)
NF-κB
MAP3K
MEK
ERK
p38 MAPK
Interleukin Related
SARS-CoV
|
Infection
Inflammation/Immunology
|
|
TriDAP (L-Ala-γ-D-Glu-meso-diaminopimelic acid) is a NOD1 agonist with a Kd value of 34.5 μM. TriDAP enhances the binding of NOD1-RICK, promotes RICK phosphorylation, and activates the NF-κB, TAK1, MEK/ERK, p38 and interferon response pathways. TriDAP downregulates Runx2 via increasing ubiquitination and reduces trabecular bone parameters. TriDAP decreases IκBα levels and increases p65 levels. TriDAP induces the secretion of proinflammatory mediators IL-8 and prostaglandins, triggers tissue inflammation and innate immune activation, and inhibits SARS-CoV-2 replication in lung epithelial cells. TriDAP increases the RANKL/OPG ratio in mice, reduces bone mass and enhances osteoclast activity, and inhibits new bone formation by decreasing the mineralization deposition rate in mice. TriDAP can be used in research related to pulpitis, chronic ulcerative colitis, Crohn's disease and SARS-CoV-2 infection .
|
-
- HY-P0007
-
|
Carbocalcitonin
|
Drug Intermediate
|
Metabolic Disease
|
|
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-108786
-
|
ENB-0040
|
Phosphatase
|
Metabolic Disease
|
|
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2 / knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) .
|
-
(5)
-
- HY-P9939
-
|
KRN23; N5KG1_C10_LH; UX-023
|
Inhibitory Antibodies
|
Metabolic Disease
Cancer
|
|
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia .
|
-
(5)
-
- HY-P991365
-
|
|
Transmembrane Glycoprotein
|
Endocrinology
|
|
DS-1501 is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. DS-1501 inhibits osteoclastogenesis. DS-1501 suppresses the decrease of lumbar spine bone mineral density (BMD) in ovariectomized (OVX) rats. DS-1501 can be used in Osteoporosis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-D0886
-
-
-
- HY-126304
-
-
-
- HY-N1499
-
-
-
- HY-D0835
-
|
Hydroxyapatite (25-45 μm)
|
Natural Products
Animals
Classification of Application Fields
Other Diseases
Disease Research Fields
Source Classification
|
Others
|
|
Hydroxylapatite (Hydroxyapatite) (25-45 μm) is a natural form of calcium phosphate and is the main mineral component of bones and teeth. Hydroxylapatite (25-45 μm) can stimulate the expression and secretion of collagen in primary human dermal fibroblasts. Hydroxylapatite (25-45 μm) has good biocompatibility, bioactivity, and bone conductivity, making it suitable for targeted drug or nucleic acid delivery. Hydroxylapatite (25-45 μm) can be used in research on osteoarthritis, gout, and atherosclerosis .
|
-
-
- HY-107245
-
-
-
- HY-15830
-
-
-
- HY-N8837
-
-
-
- HY-N1499R
-
-
-
- HY-N19066
-
|
|
Structural Classification
Extract
|
Others
|
|
Cissus quadrangularis extract contains a variety of bioactive compounds, such as flavonoids, phenolic acids, carotenoids, triterpenoids, vitamins, 3-ketosteroids, minerals, and sterols. Cissus quadrangularis extract can promote fracture healing, reduce bone loss, and increase bone density.
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-A0020S
-
|
|
|
Eldecalcitol-d6 is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: